Safety, tolerability, pharmacodynamics and pharmacokinetics following once‐daily doses of BI 187004, an inhibitor of 11 beta‐hydroxysteroid dehydrogenase‐1, over 28 days in patients with type 2 diabetes mellitus and overweight or obesity

AIMS: To study the oral 11 beta‐hydroxysteroid dehydrogenase‐1 (11β‐HSD1) inhibitor BI 187004 (NCT02150824), as monotherapy and in combination with metformin, versus placebo in patients with type 2 diabetes mellitus (T2DM) affected by overweight or obesity. MATERIALS AND METHODS: This Phase II, rand...

Descripción completa

Detalles Bibliográficos
Autores principales: Bianzano, Susanna, Nordaby, Matias, Plum‐Mörschel, Leona, Peil, Barbara, Heise, Tim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10107759/
https://www.ncbi.nlm.nih.gov/pubmed/36478142
http://dx.doi.org/10.1111/dom.14932

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10107759/
https://www.ncbi.nlm.nih.gov/pubmed/36478142
http://dx.doi.org/10.1111/dom.14932

Ejemplares similares